Expired
Lead Plaintiff Deadline
Nov 16, 2020
Choose your preferred way to stay informed of new case launches and settlement deadlines
(i) the Company's orally administered chemotherapy agent, tesetaxel, was not as safe or well-tolerated as the Company had led investors to believe; (ii) consequently, tesetaxel’s commercial viability as a cancer treatment was overstated; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
In order to be eligible to join the ODT class action lawsuit, you must have incurred a loss on shares of Odonate purchased during the class period listed above.
If you suffered a loss in Odonate during the relevant time frame or pursuant to the relevant offering(s), you have until November 16, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
TOP
